Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting
October 02 2018 - 4:30PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced that nine abstracts have been
accepted for poster presentation at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting, which is being held
from November 7-11, 2018 in Washington, D.C.
Details of Arcus’s poster presentations are as follows.
AB928 (dual A2aR/A2bR
antagonist)Title: Development of biomarkers to
assess adenosine generation & activity in support of clinical
trials conducted with the adenosine receptor antagonist
AB928Poster Number: P35; Abstract ID: 10513Poster
Presentation Hours: Friday, Nov. 9, from 12:45 – 2:15 pm. and
6:30 – 8 pm ETPoster Hall Location: Hall E
Title: Selection of optimized drug candidates, dosing
regimen, pharmacodynamic endpoints, tumor types, and biomarkers for
translating inhibition of the adenosine pathway into effective
anti-tumor activity.Poster Number: P668; Abstract ID:
10724Poster Presentation Hours: Saturday, Nov. 10 from 12:20
– 1:50 pm and 7:00 – 8:30 pm ETPoster Hall Location: Hall
E
Title: A phase 1/1b study to evaluate the safety and
tolerability of AB928, a novel dual adenosine receptor antagonist,
in combination with chemotherapy in patients with breast or
gynecologic malignanciesPoster Number: P320 (Trial in Progress); Abstract ID:
10688Poster Presentation Hours: Saturday, Nov. 10 from 12:20
– 1:50 pm and 7:00 – 8:30 pm ETPoster Hall Location: Hall
E
Title: A phase 1/1b study to evaluate the safety and
tolerability of AB928, a novel dual adenosine receptor antagonist,
in combination with chemotherapy in patients with gastrointestinal
malignanciesPoster Number: P321 (Trial
in Progress); Abstract ID: 10700Poster
Presentation Hours: Friday, Nov. 9, from 12:45 – 2:15 pm. and
6:30 – 8 pm ETPoster Hall Location: Hall E
Title: A phase 1/1b study to evaluate the safety and
tolerability of AB928, a novel dual adenosine receptor antagonist,
in combination with carboplatin/pemetrexed and pembrolizumab in
lung cancer patientsPoster Number: P322 (Trial in Progress); Abstract ID:
10706Poster Presentation Hours: Saturday, Nov. 10 from 12:20
– 1:50 pm and 7:00 – 8:30 pm ETPoster Hall Location: Hall
E
Title: A phase 1 study to evaluate the safety and
tolerability of AB928, a novel dual adenosine receptor antagonist,
with AB122, a programmed cell death-1 inhibitor, in patients with
advanced malignanciesPoster Number: P323 (Trial in Progress); Abstract ID:
10711Poster Presentation Hours: Friday, Nov. 9, from 12:45 –
2:15 pm. and 6:30 – 8 pm ETPoster Hall Location: Hall E
AB122 (anti-PD-1
antibody)Title: Preliminary results from an
ongoing Phase 1 study of AB122, an anti-programmed cell death-1
(PD-1) monoclonal antibody, in patients with advanced solid
tumors.Poster Number: P673; Abstract ID:
10638Poster Presentation Hours: Friday, Nov. 9, from 12:45 –
2:15 pm. and 6:30 – 8 pm ETPoster Hall Location: Hall E
Title: Development of a robust, simplified method to
measure receptor occupancy in peripheral blood from patients
treated with a novel anti-PD1 agent, AB122.Poster Number:
P15; Abstract ID: 10495Poster Presentation Hours:
Friday, Nov. 9, from 12:45 – 2:15 pm. and 6:30 – 8 pm ETPoster
Hall Location: Hall E
AB154 (anti-TIGIT
antibody)Title: Preclinical characterization of
AB154, a fully humanized anti-TIGIT antibody, for use in
combination therapiesPoster Number: P697; Abstract
ID: 10538Poster Presentation Hours: Friday, Nov. 9, from
12:45 – 2:15 pm. and 6:30 – 8 pm ETPoster Hall Location:
Hall E
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer immunotherapies. Arcus
has several programs targeting important immuno-oncology pathways,
including a dual adenosine receptor antagonist AB928, which is in a
Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is in a Phase
1 trial to evaluate AB154 as monotherapy and in combination with
AB122, and AB680, a small molecule inhibitor of CD73, which is in
IND-enabling studies. Arcus has extensive in-house expertise
in medicinal chemistry, immunology, biochemistry, pharmacology and
structural biology. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181002006073/en/
Arcus Biosciences, Inc.Jennifer Jarrett,
510-694-6261jjarrett@arcusbio.comNicole Arndt,
510-284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Apr 2023 to Apr 2024